Teniposide (VM-26) in patients with non-squamous-cell carcinoma of the cervix. A phase II trial of the gynecologie oncology group

H. B. Muss, B. N. Bundy, F. T. Given, Frederick Stehman

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Twenty-three evaluable patients with non-squamous-cell carcinoma of the cervix were treated with teniposide 100 mg/m2 per week administered as a 30-60 min infusion. Escalations of 20 mg/m2 per week to a maximum dose of 160 mg/m2 were performed in patients without toxicity. Thirteen of the 23 patients had no prior chemotherapy. One patient had a partial response (95% confidence intervals for response ≤ 19%). Toxicity was minimal. Seven patients had white blood cell counts of less than 2,000/mm3 but only one had less than 1.000/mm3. No patients had platelet counts less than 50,000/mm3, and no bleeding or septic episodes were noted. Two patients had mild nausea and seven had mild nausea and vomiting. Teniposide displays no major activity in patients with non-squamous-cell cervical cancer.

Original languageEnglish (US)
Pages (from-to)117-118
Number of pages2
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume13
Issue number2
StatePublished - 1990
Externally publishedYes

Fingerprint

Teniposide
Cervix Uteri
Carcinoma
Nausea
Platelet Count
Leukocyte Count
Uterine Cervical Neoplasms
Vomiting
Confidence Intervals
Hemorrhage
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{43923930f0054d2c9b0cc617327688c9,
title = "Teniposide (VM-26) in patients with non-squamous-cell carcinoma of the cervix. A phase II trial of the gynecologie oncology group",
abstract = "Twenty-three evaluable patients with non-squamous-cell carcinoma of the cervix were treated with teniposide 100 mg/m2 per week administered as a 30-60 min infusion. Escalations of 20 mg/m2 per week to a maximum dose of 160 mg/m2 were performed in patients without toxicity. Thirteen of the 23 patients had no prior chemotherapy. One patient had a partial response (95{\%} confidence intervals for response ≤ 19{\%}). Toxicity was minimal. Seven patients had white blood cell counts of less than 2,000/mm3 but only one had less than 1.000/mm3. No patients had platelet counts less than 50,000/mm3, and no bleeding or septic episodes were noted. Two patients had mild nausea and seven had mild nausea and vomiting. Teniposide displays no major activity in patients with non-squamous-cell cervical cancer.",
author = "Muss, {H. B.} and Bundy, {B. N.} and Given, {F. T.} and Frederick Stehman",
year = "1990",
language = "English (US)",
volume = "13",
pages = "117--118",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Teniposide (VM-26) in patients with non-squamous-cell carcinoma of the cervix. A phase II trial of the gynecologie oncology group

AU - Muss, H. B.

AU - Bundy, B. N.

AU - Given, F. T.

AU - Stehman, Frederick

PY - 1990

Y1 - 1990

N2 - Twenty-three evaluable patients with non-squamous-cell carcinoma of the cervix were treated with teniposide 100 mg/m2 per week administered as a 30-60 min infusion. Escalations of 20 mg/m2 per week to a maximum dose of 160 mg/m2 were performed in patients without toxicity. Thirteen of the 23 patients had no prior chemotherapy. One patient had a partial response (95% confidence intervals for response ≤ 19%). Toxicity was minimal. Seven patients had white blood cell counts of less than 2,000/mm3 but only one had less than 1.000/mm3. No patients had platelet counts less than 50,000/mm3, and no bleeding or septic episodes were noted. Two patients had mild nausea and seven had mild nausea and vomiting. Teniposide displays no major activity in patients with non-squamous-cell cervical cancer.

AB - Twenty-three evaluable patients with non-squamous-cell carcinoma of the cervix were treated with teniposide 100 mg/m2 per week administered as a 30-60 min infusion. Escalations of 20 mg/m2 per week to a maximum dose of 160 mg/m2 were performed in patients without toxicity. Thirteen of the 23 patients had no prior chemotherapy. One patient had a partial response (95% confidence intervals for response ≤ 19%). Toxicity was minimal. Seven patients had white blood cell counts of less than 2,000/mm3 but only one had less than 1.000/mm3. No patients had platelet counts less than 50,000/mm3, and no bleeding or septic episodes were noted. Two patients had mild nausea and seven had mild nausea and vomiting. Teniposide displays no major activity in patients with non-squamous-cell cervical cancer.

UR - http://www.scopus.com/inward/record.url?scp=0025313809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025313809&partnerID=8YFLogxK

M3 - Article

C2 - 2316480

AN - SCOPUS:0025313809

VL - 13

SP - 117

EP - 118

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -